Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors

NCT01332721 is registered in ClinicalTrials.gov with Tracon Pharmaceuticals Inc. as lead sponsor.

NCT NCT01332721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01332721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase 1B Dose-Escalation Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors
Lead sponsor
Tracon Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2011
Completion date
December 31, 2013
Enrollment
38 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adult solid tumor